DAX19.885 -0,4%ESt504.862 -0,3%Top 10 Crypto15,18 +0,5%Dow42.840 +1,2%Nas19.573 +1,0%Bitcoin91.000 -2,4%Euro1,0434 +0,7%Öl72,98 +0,4%Gold2.621 ±0,0%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Novo Nordisk A3EU6F NVIDIA 918422 Tesla A1CX3T Volkswagen (VW) vz. 766403 Sirius XM A1W8XE Palantir A2QA4J Allianz 840400 Rheinmetall 703000 Amazon 906866 Bayer BAY001 Apple 865985 BASF BASF11 Mercedes-Benz Group (ex Daimler) 710000 MicroStrategy 722713 ASML NV A1J4U4
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
US-Börsen mit versöhnlichem Wochenausklang -- DAX geht tiefer ins Wochenende -- Novo Nordisk-Therapie enttäuscht in Studie -- Bitcoin fällt tief -- D-Wave, FedEx im Fokus
Top News
Goldpreis, Weizenpreis & Co.: Wie sich die Rohstoffkurse am Sonntagabend entwickeln Goldpreis, Weizenpreis & Co.: Wie sich die Rohstoffkurse am Sonntagabend entwickeln
Sperre für TikTok: Albanien will Zugang für ein Jahr sperren - Trump will TikTok vielleicht noch eine Weile behalten Sperre für TikTok: Albanien will Zugang für ein Jahr sperren - Trump will TikTok vielleicht noch eine Weile behalten
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Gilead Sciences Aktie

NeuKaufenVerkaufen
Aktien-Sparplan anlegen
88,97 EUR +1,96 EUR +2,25 %
FSE
92,57 USD +1,46 USD +1,60 %
nachbörslich
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.110,57 Mrd. EUR

KGV17,99Div. Rendite3,70%

WKN885823

ISINUS3755581036

SymbolGILD

Gilead Sciences Aktien News

DatumMeistgelesen
BenzingaHere's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today
BenzingaThis Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
ZacksGilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
ZacksGilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts
ZacksGilead Sciences (GILD) Increases Yet Falls Behind Market: What Investors Need to Know
BenzingaPeeling Back The Layers: Exploring Gilead Sciences Through Analyst Insights
ZacksGilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
New York TimesGilead Agrees to Allow Generic Version of Groundbreaking H.I.V. Shot in Poor Countries
PR NewswireHetero Signs Voluntary Licensing Agreement with Gilead to Transform Global HIV response, Expanding Access to Groundbreaking Lenacapavir to 120 high-incidence countries
PR NewswireHetero Signs Voluntary Licensing Agreement with Gilead to Transform Global HIV response, Expanding Access to Groundbreaking Lenacapavir to 120 high-incidence countries
PR NewswireHetero Signs Voluntary Licensing Agreement with Gilead to Transform Global HIV response, Expanding Access to Groundbreaking Lenacapavir to 120 high-incidence countries
ZacksGilead Sciences (GILD) Increases Despite Market Slip: Here's What You Need to Know
ZacksGilead Sciences (GILD) Stock Slides as Market Rises: Facts to Know Before You Trade
BenzingaGilead Sciences Recalls One Lot Of Its COVID-19 Treatment Due To Presence Of Glass Particles
BenzingaGilead Sciences Unusual Options Activity For September 20
ZacksGilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
ZacksGilead Sciences (GILD) Stock Sinks As Market Gains: Here's Why
ZacksGilead Stock Rises as HIV Prevention Injection Meets Study Goals
MotleyFoolWhy Gilead Sciences Stock Thrashed the Market Today
BenzingaGilead Unveils 'Remarkable Outcomes' From Late-Stage Lenacapavir Study Showing Promise In Preventing HIV Infections
BenzingaWhat the Options Market Tells Us About Gilead Sciences
ZacksGilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
BenzingaPeering Into Gilead Sciences's Recent Short Interest
BenzingaUnveiling 10 Analyst Insights On Gilead Sciences
BenzingaGilead Sciences Options Trading: A Deep Dive into Market Sentiment
BenzingaDecoding Gilead Sciences's Options Activity: What's the Big Picture?
ZacksGilead (GILD) Gains 16.8% in 3 Months: How Should You Play the Stock?
ZacksInvestors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
BenzingaPeering Into Gilead Sciences's Recent Short Interest
ZacksGilead (GILD) Obtains FDA Approval for PBC Drug Livdelzi
BenzingaExpert Outlook: Gilead Sciences Through The Eyes Of 8 Analysts
BenzingaAnalysts Cite Improved Investor Sentiment For Gilead, But Warn of Limited Growth at Current Stock Levels
ZacksGilead (GILD) Q2 Earnings Beat, Annual Profit Guidance Raised
MotleyFoolGilead Sciences (GILD) Q2 2024 Earnings Call Transcript
MarketWatchGilead Sciences posts higher Q2 profit and revenue on increased sales
ZacksGilead (GILD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
ZacksGilead Sciences (GILD) Q2 Earnings and Revenues Beat Estimates
Benzinga$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today
ZacksCountdown to Gilead (GILD) Q2 Earnings: Wall Street Forecasts for Key Metrics
ZacksShould You Buy, Sell or Hold Gilead Sciences (GILD) Before Q2 Earnings?

Gilead Sciences News

Gilead Sciences News: auf dieser Seite finden Sie alle Gilead Sciences News und Nachrichten zur Gilead Sciences Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Gilead Sciences News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Gilead Sciences News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.